Clinical

ba0003OP1 | Clinical

A transdermal patch delivering the PTHrP_1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

ba0003OP2 | Clinical

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

ba0003OP3 | Clinical

PTH treatment induces WNT10b expression in humans lymphoid cells

ba0003OP4 | Clinical

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

ba0003OP5 | Clinical

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

ba0003OP6 | Clinical

Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass

ba0003OP7 | Clinical

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

ba0003OP8 | Clinical

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

ba0003OP9 | Clinical

Zoledronate prevents lactation induced loss of bone strength and micro-architecture

ba0003OP10 | Clinical

Zoledronate reverses bone marrow adiposity in disuse osteopenic rats

ba0003OP11 | Clinical

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

ba0003OP12 | Clinical

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

ba0003OP13 | Clinical

Decrease in expression of MMP3 in osteoblast protects against bone loss

ba0003OP14 | Clinical

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

ba0003OP15 | Clinical

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

ba0003OP16 | Clinical

The impact of common comorbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study

ba0003OP17 | Clinical

Dynamic changes in bone marrow adiposity during the menstrual cycle

ba0003OP18 | Clinical

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

ba0003OP19 | Clinical

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

ba0003OP20 | Clinical

No beneficial effects of vitamin D supplementation in muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial.

Bone Abstracts

European Calcified Tissue Society Congress 2014

Oral Posters

A transdermal patch delivering the PTHrP_1--34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

PTH treatment induces WNT10b expression in humans lymphoid cells

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Zoledronate prevents lactation induced loss of bone strength and micro-architecture

Zoledronate reverses bone marrow adiposity in disuse osteopenic rats

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

Decrease in expression of MMP3 in osteoblast protects against bone loss

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

The impact of common comorbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study

Dynamic changes in bone marrow adiposity during the menstrual cycle

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

No beneficial effects of vitamin D supplementation in muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial.

BiosciAbstracts